BeiGene’s Tevimbra Recommended for EU Approval in Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist proposing to rename...
HKG: 6160
BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...
BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...
BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
BeiGene’s Tevimbra Receives FDA Approval for HER2-Negative Gastric Cancer Treatment
China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that the...
BeiGene Rebrands to BeOne Medicines Ltd, Ticker Symbol Changes to “ONC”
China-based BeiGene Ltd, listed on Nasdaq (NASDAQ: BGNE, HKG: 6160, SHA: 688235), has announced a...
BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039
BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement...
Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL
US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...
Mabwell Bioscience Enters Licensing Agreement for Biosimilar Denosumab in Peru
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its...
Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...
BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments
China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...
Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment
Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the...
BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa
China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...
BeiGene Ltd to Become BeOne Medicines Ltd, Emphasizing Global Oncology Commitment
China-based biotechnology company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a proposed...
BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care
BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading global innovator in oncology treatments,...
BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its...
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...
BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option
BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...
BeiGene’s Tevimbra Receives CHMP Recommendation for Expanded Use in G/GEJ and ESCC Cancers in EU
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has received...
Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies
The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...